Tramway Ventures

Build With Robots develops robotic systems aimed at enhancing worker safety and efficiency in various industries, including logistics, construction, and entertainment. The company focuses on creating technology that allows robots to work alongside human employees, taking on tasks that are considered dirty, dangerous, or dull, rather than replacing human jobs. Their proprietary disinfection robots utilize fogging technology to effectively sanitize large spaces, helping organizations to mitigate health risks associated with COVID-19 and other airborne particulates. By integrating robotics into the workforce, Build With Robots aims to improve the overall work environment and empower employees while ensuring their safety.

Nob Hill Therapeutics, Inc. is a Delaware Corporation founded in 2016 and based in Fayetteville, Arkansas. The company specializes in developing and marketing DryNeb, a pioneering dry powder nebulizer designed to treat severe respiratory diseases. This innovative device distinguishes itself from traditional aerosol mist nebulizers by being compact, handheld, and portable, providing a more user-friendly experience. The DryNeb nebulizer utilizes a unique mechanism that disperses medication through mechanical collisions within a dispersion chamber, ensuring consistent delivery independent of the patient's inhalation force. This technology allows for effective pulmonary drug delivery, which is increasingly important for both local and systemic treatments due to its high bioavailability and rapid action. Nob Hill Therapeutics has exclusively licensed this technology from the University of New Mexico, positioning itself to address significant market opportunities in pulmonary drug delivery.

Circular Genomics is a company based in Albuquerque, New Mexico, specializing in the development of circular RNA diagnostics to enhance precision medicine in the treatment of neurological and psychiatric conditions. Founded in 2021, the company aims to improve the diagnosis and treatment of depressive disorders by utilizing circular RNA as a novel biomarker. This innovative approach allows for evidence-based treatment strategies, significantly reducing the time required for patients to achieve a therapeutic response. By focusing on the potential of circular RNA, Circular Genomics is positioning itself as a leader in the field of psychiatric and neurological diagnostics, enabling healthcare professionals to better address complex mental health issues.

Vitazi.ai is an early-stage start-up located in Santa Fe, New Mexico, specializing in the development of diagnostic technology for disease detection through artificial intelligence. The company has created the first comprehensive end-to-end solution for diabetic retinopathy detection, integrating both hardware and software tailored to the specific needs of healthcare providers. This innovative system enables real-time and accurate evaluation of patients, helping to meet quality metrics and improve reimbursement processes while addressing the long-term challenges associated with preventable vision loss and blindness. Vitazi.ai aims to enhance the capabilities of healthcare professionals and improve patient outcomes through its advanced diagnostic tools.

Circular Genomics is a company based in Albuquerque, New Mexico, specializing in the development of circular RNA diagnostics to enhance precision medicine in the treatment of neurological and psychiatric conditions. Founded in 2021, the company aims to improve the diagnosis and treatment of depressive disorders by utilizing circular RNA as a novel biomarker. This innovative approach allows for evidence-based treatment strategies, significantly reducing the time required for patients to achieve a therapeutic response. By focusing on the potential of circular RNA, Circular Genomics is positioning itself as a leader in the field of psychiatric and neurological diagnostics, enabling healthcare professionals to better address complex mental health issues.

Armonica Technologies is an early-stage medtech company specializing in long-read DNA sequencing technology aimed at precision medicine applications. Named after Benjamin Franklin's Glass Armonica, the company has developed a proprietary platform that can sequence a complete human genome in minutes. This innovative technology utilizes nanochannels to guide single nucleic acid molecules through nanopores, allowing for optical readout through Raman spectroscopy. By overcoming the limitations of existing sequencing technologies, Armonica's platform offers life science researchers and clinicians a comprehensive understanding of the genome, including critical insights into all epigenetic modifications. The company holds a portfolio of patented and patent-pending technologies licensed from STC.UNM, positioning it at the forefront of advancements in genomic sequencing.

WaveDyn Vision is an early-stage medical device company with innovative wavefront diagnostic technology for use in the vision care industry. It plans to leverage its proprietary dynamic wavefront measurement technology to yield new insights into assessing visual performance, advancing treatment options, and improving the quality of life for the visually impaired. The company was founded in 2019 and is based in Albuquerque, New Mexico.

WaveFront Dynamics is a medical device company specializing in advanced wavefront diagnostic technology tailored for the vision care sector. The company develops instruments that assess the visual performance of the human eye by measuring changes dynamically over time, rather than relying on a single snapshot. This innovative approach allows for comprehensive evaluations of the eye, facilitating improved treatment planning for complex visual dysfunctions. By leveraging dynamic wavefront measurement capabilities, WaveFront Dynamics aims to enhance the effectiveness of ophthalmic treatments and support healthcare professionals in delivering optimal patient care.

BennuBio, Inc. is a technology company specializing in the development of flow cytometry equipment designed for the sorting and analysis of cells and particles in various applications, particularly those requiring the recovery of rare cells. The company offers The Velocyt system, which enables the detection of rare events such as activated T cells, circulating tumor cells, and fetal cells in maternal blood, supporting advancements in personalized medicine and drug discovery. Additionally, BennuBio provides spheroid generation systems and high-volume sorting systems, along with technical and application support services. Founded in 2018 and based in Albuquerque, New Mexico, BennuBio focuses on delivering innovative cell analysis solutions that accommodate a wide range of sample sizes and particle dimensions.

BennuBio, Inc. is a technology company specializing in the development of flow cytometry equipment designed for the sorting and analysis of cells and particles in various applications, particularly those requiring the recovery of rare cells. The company offers The Velocyt system, which enables the detection of rare events such as activated T cells, circulating tumor cells, and fetal cells in maternal blood, supporting advancements in personalized medicine and drug discovery. Additionally, BennuBio provides spheroid generation systems and high-volume sorting systems, along with technical and application support services. Founded in 2018 and based in Albuquerque, New Mexico, BennuBio focuses on delivering innovative cell analysis solutions that accommodate a wide range of sample sizes and particle dimensions.

Armonica Technologies is an early-stage medtech company specializing in long-read DNA sequencing technology aimed at precision medicine applications. Named after Benjamin Franklin's Glass Armonica, the company has developed a proprietary platform that can sequence a complete human genome in minutes. This innovative technology utilizes nanochannels to guide single nucleic acid molecules through nanopores, allowing for optical readout through Raman spectroscopy. By overcoming the limitations of existing sequencing technologies, Armonica's platform offers life science researchers and clinicians a comprehensive understanding of the genome, including critical insights into all epigenetic modifications. The company holds a portfolio of patented and patent-pending technologies licensed from STC.UNM, positioning it at the forefront of advancements in genomic sequencing.